Email
Print
HIV/AIDS Monitoring Tests Market - Forecast(2024 - 2030)
HIV/AIDS Monitoring Tests Market Overview
HIV/AIDS Monitoring Tests Market size is estimated to reach $718.4 million by 2027, growing at a CAGR of 7.3% during the forecast period 2022-2027. As per the Centers for Disease Control and Prevention (CDC), HIV (Human Immunodeficiency Virus) tests for screening and diagnosis include antibody tests, antigen/antibody tests and nucleic acid tests (NATs). Nucleic acid tests directly look for the existence of the virus in the blood. Scientists have established a test that can be carried out on saliva samples. The enzyme-linked immunosorbent assay (ELISA) tests blood samples of patients for antibodies. The immunoblot assay (IBA) and indirect immunofluorescence assay methods are two suggested confirmation tests for EIA (Enzyme Immunoassay)-positive sera. The radio-immunoprecipitation assay (RIPA) needs HIV to be developed in cell culture in the presence of a radioactive label, refined and disturbed (100–102). The increasing predominance of HIV incidents in young people is set to drive the HIV/AIDS Monitoring Tests Market. The rising application of antibody tests is set to propel the growth of the HIV/AIDS Monitoring Tests Industry during the forecast period 2022-2027. This represents the HIV/AIDS Monitoring Tests Industry Outlook.
HIV/AIDS Monitoring Tests Market Report Coverage
The report: “HIV/AIDS Monitoring Tests Market Report
- Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the
following segments in the HIV/AIDS
Monitoring Tests Market.
Key Takeaways
- Geographically, North America (HIV/AIDS Monitoring Tests market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the existence of key players providing high-end testing equipment in the North American region.
- HIV/AIDS Monitoring Tests Market growth is being driven by the rising awareness of efficient HIV/AIDS treatment techniques like antibody tests in blood samples and saliva samples. However, the dearth of proficient medical professionals for conducting HIV/AIDS Monitoring Tests is one of the major factors hampering the growth of the HIV/AIDS Monitoring Tests Market.
- HIV/AIDS Monitoring Tests Market Detailed Analysis on the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the HIV/AIDS Monitoring Tests Market report.
HIV/AIDS Monitoring Tests Market: Market Share (%) by Region, 2021
For more details on this report - Request for Sample
HIV/AIDS Monitoring Tests Market Segment Analysis – By Test Type
The HIV/AIDS Monitoring Tests Market based on test type can be further segmented into Antibody Tests, Viral Load Tests, CD4 Tests and others. The Antibody Tests Segment held the largest HIV/AIDS Monitoring Tests market share in 2021. This growth is owing to the surging application of antibody tests to detect HIV antibodies in blood samples or saliva samples. The increasing predominance of HIV/AIDS is further propelling the growth of the Antibody Tests segment. Furthermore, the Viral Load Tests segment is estimated to grow with the fastest CAGR of 8.1% during the forecast period 2022-2027. It is due to the increasing application of viral load tests to diagnose HIV in people suspected of infection, to inspect if the medications offered for HIV infection are efficient and to track alterations that happen during infection.
HIV/AIDS Monitoring Tests Market Segment Analysis - By End-user
The HIV/AIDS Monitoring Tests Market based on end-user can be further segmented into Diagnostic Laboratories, Hospitals and others. The Hospitals Segment held the largest HIV/AIDS Monitoring Tests market share in 2021. This growth is owing to the existence of a complete spectrum of preventive, supportive and curative services accessible in district hospitals of high prevalence districts in countries like India. The HIV/AIDS prevention services inclusive of treatment and cure for sexually transmitted infections presented by hospitals are further propelling the growth of this segment. Furthermore, the Diagnostic Laboratories segment is estimated to grow with the fastest CAGR of 8.3% during the forecast period 2022-2027 owing to the recommendation of antigen/antibody tests to be performed in laboratories, typically in the US and the application of novel methodologies in laboratories like the HIV antibody-based assays.
HIV/AIDS Monitoring Tests Market Segment Analysis - By Geography
North America (HIV/AIDS Monitoring Tests Market) held the largest HIV/AIDS Monitoring Tests market share with 34% of the overall market in 2021. The growth of this region is due to the high predominance of HIV/AIDS in the North American region. The increasing application of antibody tests is further propelling the growth of the HIV/AIDS Monitoring Tests Industry. This further contributes to the HIV/AIDS Monitoring Tests Industry Outlook in the North American region. However, the Asia-pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the high epidemic burden of HIV/AIDS in the Asia-pacific region. The rising government initiatives to remove HIV infections are further fuelling the progress of the HIV/AIDS Monitoring Tests Market in the Asia-pacific region.
HIV/AIDS Monitoring Tests Market Drivers
Surging Applications of Nucleic Acid Tests:
The sensitivity of HIV tests is nearly 99-100%. A Nucleic Acid Test (NAT) examines the presence of the real virus in the blood. With nucleic acid tests, the health care provider would take blood from the vein and send the sample to a laboratory for testing. This test can identify if a person has HIV or how much virus exists in the blood (HIV viral load test). A nucleic acid test can discover HIV earlier than other kinds of tests. The surging applications of nucleic acid tests are therefore fuelling the growth of the HIV/AIDS Monitoring Tests Market during the forecast period 2022-2027.
Soaring Applications of Enzyme-Linked Immunosorbent Assay (ELISA):
The enzyme-linked immunosorbent assay (ELISA) tests blood samples of patients for antibodies. Oral fluid (not saliva samples), accumulated from the cheeks and gums, may also be utilized to carry out an ELISA A positive (reactive). Enzyme-linked immunosorbent assay for all samples must be utilized with a follow-up (confirmatory) test, like the Western blot test, to make a positive diagnosis. When utilized in integration with the confirmatory Western blot test, ELISA tests are 99.9% precise. These soaring applications of Enzyme-Linked Immunosorbent Assay (ELISA) are therefore driving the growth of the HIV/AIDS Monitoring Tests Industry. This further contributes to the HIV/AIDS Monitoring Tests Industry Outlook during the forecast period 2022-2027.
HIV/AIDS Monitoring Tests Market Challenges
Limitations of HIV Tests:
As per CDC, nearly 1.2 million people in the U.S. have HIV and around 13 percent of them are not aware of it and require testing. While numerous rapid tests for HIV infection display a soaring level of sensitivity and specificity, it is acknowledged that most have restraints in comparison with traditional tests. The most typical disadvantage is the extended window period while discovering the existence of HIV antibodies by simple lateral flow technology. These issues are thus hampering the growth of the HIV/AIDS Monitoring Tests Market.
HIV/AIDS Monitoring Tests Industry Outlook
Product launches, development of novel tests, mergers and acquisitions, partnerships, collaborations and R&D activities are key strategies adopted by players in the HIV/AIDS Monitoring Tests Market. The top 10 companies in the HIV/AIDS Monitoring Tests market are:
- Alere Inc.
- Abbott Laboratories
- OraSure Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Chembio Diagnostics Systems, Inc.
- Quest Diagnostics, Inc.
- Siemens Healthineers
- Abbott Molecular Inc.
- Calypte Biomedical Corporation
- F. Hoffmann-La Roche Ltd.
Recent Developments
- In January 2022, OraSure Technologies, Inc. introduced its OraQuick® HIV Self-Test in Europe. This is an oral swab in-home test for HIV-1 and HIV-2. OraQuick® is the world’s first in-home oral HIV Test.
- In May 2020, OraSure Technologies, Inc. filed into a definitive agreement to gain privately owned UrSure, Inc. for cash. The acquisition reinforced the leadership position of Orasure in the HIV field. UrSure is establishing and commercializing products that assess adherence to HIV medicines.